Engineered Angiotensin II Analog Strengthens Heart Without Raising Blood Pressure
C-terminal modification of angiotensin II created compound 12, a biased AT1R agonist that enhances heart contractility while minimizing blood pressure elevation through selective β-arrestin over Gαq signaling.
Quick Facts
What This Study Found
Compound 12 showed low Gαq/potent β-arrestin activity at AT1R, enhanced left ventricular ejection fraction with limited pressor response in normotensive rats, and accessed a unique deep allosteric pocket in molecular modeling.
Key Numbers
How They Did This
Synthesis of AngII Phe8 analogs, in vitro Gαq and β-arrestin signaling profiling, in vivo hemodynamic assessment in normotensive rats, and molecular modeling of AT1R binding.
Why This Research Matters
Heart failure needs better drugs. A peptide that strengthens the failing heart without raising blood pressure addresses a critical unmet need.
The Bigger Picture
Biased agonism — selectively activating one signaling pathway over another — is a powerful drug design principle. Achieving it through peptide modification demonstrates the precision possible with peptide therapeutics.
What This Study Doesn't Tell Us
Preclinical rat data. Normotensive rats may respond differently than heart failure models. Long-term cardiac effects unknown.
Questions This Raises
- ?Would compound 12 improve cardiac function in heart failure models?
- ?Can the biased signaling be further optimized through additional modifications?
- ?What is the pharmacokinetic profile of compound 12?
Trust & Context
- Key Stat:
- Heart boost, no BP rise Compound 12 strengthened heart contractions in rats while barely affecting blood pressure — separating beneficial from harmful angiotensin effects
- Evidence Grade:
- Preclinical proof-of-concept with in vitro signaling and in vivo hemodynamic validation. Novel biased agonist with strong rationale.
- Study Age:
- Published in 2025.
- Original Title:
- Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.
- Published In:
- Journal of medicinal chemistry, 69(3), 2063-2081 (2026)
- Authors:
- Hadjadj, Margot, Hassanzadeh, Malihe, Martel, Justin, Roy, Marie-Frédérique, Giguère, Hugo, Murza, Alexandre, Holleran, Brian J, Namkung, Yoon, Froehlich, Ulrike, Leduc, Richard, Auger-Messier, Mannix, Laporte, Stéphane A, Boudreault, Pierre-Luc
- Database ID:
- RPEP-15249
Evidence Hierarchy
Frequently Asked Questions
How can angiotensin strengthen the heart without raising blood pressure?
Angiotensin II activates two different pathways through the same receptor. Compound 12 was engineered to selectively activate the heart-strengthening pathway while barely touching the blood pressure-raising one.
Could this treat heart failure?
Potentially. A drug that makes the heart pump stronger without raising blood pressure would be ideal for heart failure patients. This needs testing in heart failure animal models and eventually human trials.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15249APA
Hadjadj, Margot; Hassanzadeh, Malihe; Martel, Justin; Roy, Marie-Frédérique; Giguère, Hugo; Murza, Alexandre; Holleran, Brian J; Namkung, Yoon; Froehlich, Ulrike; Leduc, Richard; Auger-Messier, Mannix; Laporte, Stéphane A; Boudreault, Pierre-Luc. (2026). Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.. Journal of medicinal chemistry, 69(3), 2063-2081. https://doi.org/10.1021/acs.jmedchem.5c01259
MLA
Hadjadj, Margot, et al. "Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.." Journal of medicinal chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.5c01259
RethinkPeptides
RethinkPeptides Research Database. "Tunable Biased Signaling of the Angiotensin II Type 1 Recept..." RPEP-15249. Retrieved from https://rethinkpeptides.com/research/hadjadj-2026-tunable-biased-signaling-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.